New cancer drug HX111 enters early human trials
Disease control
Not yet recruiting
This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…
Phase: PHASE1, PHASE2 • Sponsor: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC